Morningstar1mon
Immutep Reports Promising New Data in Head and Neck Cancer at ESMO Immuno-Oncology 2024
The ESMO IO poster is available on the Posters & Publications section of Immutep’s website. Immutep is a clinical-stage biotechnology company developing novel LAG-3 immunotherapy for cancer ...
Medindia1mon
2024 ESMO Asia: TransThera announces clinical data of tinengotinib in combination with atezolizumab (PD-L1) in biliary tract carcinoma (BTC)
Dec. 9, 2024 /PRNewswire/ -- TransThera Sciences Nanjing, Inc. (the "TransThera") announced the poster presentation at the 2024 European Society For Medical Oncology (ESMO) Asia Congress to ...
Business Insider1mon
EnnoDC presents preliminary data for immunotherapy candidate CD40.HVac in HPV+ oropharyngeal cancer at ESMO IO 2024
EnnoDC presents preliminary data for immunotherapy candidate CD40.HVac in HPV+ oropharyngeal cancer at ESMO IO 2024 Paris ... Switzerland. The poster titled, “Preliminary results of a ...
Nasdaq1mon
Daiichi Sankyo Highlights Progress Across Oncology Portfolio in Multiple Solid and Blood Cancers at ESMO Asia, SABCS and ASH
Innovation in Lung, Breast, Gastric and Biliary Tract Cancer at ESMO Asia Late-breaking data ... Trial-in-progress posters will feature the trial designs from a sub-protocol of a phase 1b master ...
Pharmabiz29d
NEC Bio presents positive interim results from phase 1 trial of NECVAX-NEO1, an AI-driven personalized oral cancer vaccine, at ESMO Congress 2024
The findings are being presented in a poster at the ESMO Immuno-Oncology Congress in Geneva, Switzerland from December 11 to 13, 2024. NECVAX-NEO1 is a personalized bacteria-based oral DNA therapeutic ...
Taiwan News1mon
2024 ESMO Asia: TransThera announces clinical data of tinengotinib in combination with atezolizumab (PD-L1) in biliary tract carcinoma (BTC)
NANJING, China and GAITHERSBURG, Md., Dec. 9, 2024 /PRNewswire/ -- TransThera Sciences Nanjing, Inc. (the "TransThera") announced the poster presentation at the 2024 European Society For Medical ...